Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | WHR1 | P49842 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18370802 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL19106406 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18370763 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18017902 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18017990 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18370754 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18370785 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18370749 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18017852 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM | |
| SCHEMBL18370767 | 1.00 | ADORA2A (0.39) | ADORA2AADORA1MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170012216-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
| US-20170012216-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170012216-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | ADORA2A 4711/4885ADORA1 4810/4885MEN1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.